These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 22001304)

  • 1. Molecular monitoring of Plasmodium falciparum resistance to antimalarial drugs after adoption of sulfadoxine-pyrimethamine plus artesunate as the first line treatment in Iran.
    Afsharpad M; Zakeri S; Pirahmadi S; Djadid ND
    Acta Trop; 2012 Jan; 121(1):13-8. PubMed ID: 22001304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of pfdhfr-pfdhps triple mutations associated with anti-malarial drugs resistance in Plasmodium falciparum isolates seven years after the adoption of sulfadoxine-pyrimethamine in combination with artesunate as first-line treatment in Iran.
    Rouhani M; Zakeri S; Pirahmadi S; Raeisi A; Djadid ND
    Infect Genet Evol; 2015 Apr; 31():183-9. PubMed ID: 25653131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular markers associated with resistance to commonly used antimalarial drugs among Plasmodium falciparum isolates from a malaria-endemic area in Taiz governorate-Yemen during the transmission season.
    Alareqi LMQ; Mahdy MAK; Lau YL; Fong MY; Abdul-Ghani R; Mahmud R
    Acta Trop; 2016 Oct; 162():174-179. PubMed ID: 27343362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
    Kateera F; Nsobya SL; Tukwasibwe S; Hakizimana E; Mutesa L; Mens PF; Grobusch MP; van Vugt M; Kumar N
    Acta Trop; 2016 Dec; 164():329-336. PubMed ID: 27647575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations.
    Hamour S; Melaku Y; Keus K; Wambugu J; Atkin S; Montgomery J; Ford N; Hook C; Checchi F
    Trans R Soc Trop Med Hyg; 2005 Jul; 99(7):548-54. PubMed ID: 15869770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.
    Schönfeld M; Barreto Miranda I; Schunk M; Maduhu I; Maboko L; Hoelscher M; Berens-Riha N; Kitua A; Löscher T
    Malar J; 2007 Jan; 6():2. PubMed ID: 17224049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Field-based evidence for linkage of mutations associated with chloroquine (pfcrt/pfmdr1) and sulfadoxine-pyrimethamine (pfdhfr/pfdhps) resistance and for the fitness cost of multiple mutations in P. falciparum.
    Osman ME; Mockenhaupt FP; Bienzle U; Elbashir MI; Giha HA
    Infect Genet Evol; 2007 Jan; 7(1):52-9. PubMed ID: 16690361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable high frequencies of sulfadoxine-pyrimethamine resistance associated mutations and absence of K13 mutations in Plasmodium falciparum 3 and 4 years after the introduction of artesunate plus sulfadoxine-pyrimethamine in Ujjain, Madhya Pradesh, India.
    Pathak A; Mårtensson A; Gawariker S; Sharma A; Diwan V; Purohit M; Ursing J
    Malar J; 2020 Aug; 19(1):290. PubMed ID: 32795288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of molecular mutations in pfdhfr, pfdhps, pfmdr1, and pfcrt genes of Plasmodium falciparum related to resistance to different anti-malarial drugs in the Bata District (Equatorial Guinea).
    Berzosa P; Esteban-Cantos A; García L; González V; Navarro M; Fernández T; Romay-Barja M; Herrador Z; Rubio JM; Ncogo P; Santana-Morales M; Valladares B; Riloha M; Benito A
    Malar J; 2017 Jan; 16(1):28. PubMed ID: 28086777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequencies distribution of dihydrofolate reductase and dihydropteroate synthetase mutant alleles associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum population from Hadhramout Governorate, Yemen.
    Bamaga OA; Mahdy MA; Lim YA
    Malar J; 2015 Dec; 14():516. PubMed ID: 26693691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.
    Wurtz N; Fall B; Pascual A; Diawara S; Sow K; Baret E; Diatta B; Fall KB; Mbaye PS; Fall F; Diémé Y; Rogier C; Bercion R; Briolant S; Wade B; Pradines B
    Malar J; 2012 Jun; 11():197. PubMed ID: 22694921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran.
    Zakeri S; Afsharpad M; Raeisi A; Djadid ND
    Malar J; 2007 Nov; 6():148. PubMed ID: 17999755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of the 437G mutation associated with sulfadoxine resistance among Plasmodium falciparum clinical isolates from Iran, three years after the introduction of sulfadoxine-pyrimethamine.
    Zakeri S; Farahani MS; Afsharpad M; Salehi M; Raeisi A; Djadid ND
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e123-8. PubMed ID: 20399698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of pfcrt but not pfmdr1 alleles with chloroquine resistance in Iranian isolates of Plasmodium falciparum.
    Zakeri S; Afsharpad M; Kazemzadeh T; Mehdizadeh K; Shabani A; Djadid ND
    Am J Trop Med Hyg; 2008 Apr; 78(4):633-40. PubMed ID: 18385361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large differences in prevalence of Pfcrt and Pfmdr1 mutations between Mwanza, Tanzania and Iganga, Uganda-a reflection of differences in policies regarding withdrawal of chloroquine?
    Kamugisha E; Bujila I; Lahdo M; Pello-Esso S; Minde M; Kongola G; Naiwumbwe H; Kiwuwa S; Kaddumukasa M; Kironde F; Swedberg G
    Acta Trop; 2012 Feb; 121(2):148-51. PubMed ID: 22118982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
    Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
    Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of pfdhfr/pfdhps alleles and declining artesunate/sulphadoxine-pyrimethamine efficacy against Plasmodium falciparum eight years after deployment in eastern Sudan.
    Gadalla NB; Abdallah TM; Atwal S; Sutherland CJ; Adam I
    Malar J; 2013 Jul; 12():255. PubMed ID: 23870667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of molecular markers of sulfadoxine-pyrimethamine and artemisinin resistance in Plasmodium falciparum from Pakistan.
    Yaqoob A; Khattak AA; Nadeem MF; Fatima H; Mbambo G; Ouattara A; Adams M; Zeeshan N; Takala-Harrison S
    Malar J; 2018 Dec; 17(1):471. PubMed ID: 30558587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Plasmodium falciparum genes associated with drug resistance in Hodh Elgharbi, a malaria hotspot near Malian-Mauritanian border.
    Ould Ahmedou Salem MS; Mint Lekweiry K; Bouchiba H; Pascual A; Pradines B; Ould Mohamed Salem Boukhary A; Briolant S; Basco LK; Bogreau H
    Malar J; 2017 Apr; 16(1):140. PubMed ID: 28381273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates.
    Dlamini SV; Beshir K; Sutherland CJ
    Malar J; 2010 Mar; 9():68. PubMed ID: 20199676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.